Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers Squibb: Deucravacitinib Applications Advance in U.S., Europe

11/29/2021 | 07:44am EST

By Colin Kellaher

Bristol-Myers Squibb Co. on Monday reported regulatory advances in the U.S. and Europe for deucravacitinib, its potential rival to Amgen Inc.'s blockbuster Otezla, in moderate to severe plaque psoriasis.

The New York biopharmaceutical company said the U.S. Food and Drug Administration accepted its new-drug application for deucravacitinib for adults with the autoimmune disorder and set a target action date of Sept. 10, 2022.

In addition, Bristol-Myers said the European Medicines Agency validated its marketing authorization application, confirming the submission is complete and beginning the centralized review process.

The applications are supported by results from a Phase 3 program that showed superior efficacy of deucravacitinib over Otezla and placebo in adults with moderate to severe plaque psoriasis, Bristol-Myers said.

Amgen bought Otezla from Celgene Corp. for $13.4 billion in a 2019 deal that paved the way for regulatory approval Celgene's $74 billion acquisition by Bristol-Myers.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

11-29-21 0744ET

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 2.60% 63.86 Delayed Quote.-0.18%
CORN FUTURES (C) - CBR (FLOOR)/C1 -0.28% 625.25 End-of-day quote.5.69%
All news about BRISTOL-MYERS SQUIBB COMPANY
01/25Metagenomi, Inc. announced that it has received $175 million in funding from a group of..
CI
01/20BRISTOL MYERS SQUIBB : Receives Approval for Abecma (idecabtagene vicleucel), the First CA..
PU
01/19Ceptur Therapeutics Inc announced that it has received $75 million in funding from a gr..
CI
01/11Evotec, Bristol Myers Expand Neurogenerative Partnership to Include New Targeted Protei..
MT
01/11Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination ..
AQ
01/11Evogene's Biomica Gets Israeli Nod To Move Ahead With Cancer Trial
MT
01/10BioAlta, Bristol Myers Squibb Partnering on Potential Cancer Treatments
MT
01/10BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab ..
PR
01/10Bioatla, Inc. Enters into a Clinical Collaboration with Bristol Myers Squibb to Investi..
CI
01/10Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement
MT
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 397 M - -
Net income 2021 6 258 M - -
Net Debt 2021 28 628 M - -
P/E ratio 2021 21,9x
Yield 2021 3,08%
Capitalization 142 B 142 B -
EV / Sales 2021 3,67x
EV / Sales 2022 3,43x
Nbr of Employees 30 250
Free-Float -
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 63,86 $
Average target price 71,98 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-0.18%141 747
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960